Carregant...
octanate(®): over 20 years of clinical experience in overcoming challenges in haemophilia A treatment
Treatment of haemophilia A with FVIII replacement has evolved over the past decades to adapt to the needs of patients. octanate®, a plasma-derived, double virus-inactivated, von Willebrand factor (VWF)-containing FVIII concentrate, has been used in clinics worldwide for over 20 years. First licensed...
Guardat en:
| Publicat a: | Ther Adv Hematol |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7171997/ https://ncbi.nlm.nih.gov/pubmed/32341775 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620720914692 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|